Radiation for prostate cancer

Lancet Oncology

Volumn 2, Issue 2, 2001, Pages 73-81

  Duchesne, Gillian M ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BRACHYTHERAPY; HUMAN; INSTRUMENTATION; MALE; METHODOLOGY; PROSTATE TUMOR; RADIATION DOSE; RADIOTHERAPY; REVIEW;

BRACHYTHERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY; RADIOTHERAPY DOSAGE;

EID: 0035262204     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00223-0     Document Type: Review

References (50)

1. Frydenberg M., Duchesne G., Stricker P.D. Management of localised prostate cancer: state of the art. Med J Aust. 169:(1):1998;11-12.
2. Perez C.A., Hanks G.E., Leibel S.A., Zietman A.L., Fuks Z., Lee W.R. Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy. Cancer. 72:1993;3156-3173.
3. Koper P.C., Stroom J.C., van Putten W.L., et al. Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys. 43:(4):1999;727-734.
4. Tait D.M., Nahum A.E., Meyer L.C., et al. Acute toxicity in pelvic radiotherapy; a randomised trial of conformal versus conventional treatment. Radiother Oncol. 42:(2):1997;121-136.
5. Dearnaley D.P., Khoo V.S., Norman A.R., et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet. 353:(9149):1999;267-272.
6. Michalski J.M., Purdy J.A., Winter K., et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys. 46:(2):2000;391-402.
7. Pollack A., Zagars G.K., Starkschall G., et al. Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys. 34:(3):1996;555-564.
8. Vicini F.A., Kestin L.L., Martinez A.A. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 45:(3):1999;553-561.
9. Valicenti R., Lu J., Pilepich M., Asbell S., Grignon D. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol. 18:2000;2740-2746.
10. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-500.
11. Zelefsky M.J., Cowen D., Fuks Z., et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer. 85:(11):1999;2460-2468.
12. Hanks G.E., Schultheiss T.E., Hanlon A.L., et al. Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. Int J Radiat Oncol Biol Phys. 37:(3):1997;543-550.
13. Hanks G.E., Hanlon A.L., Schultheiss T.E., et al. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys. 41:(3):1998;501-510.
14. Fukunaga-Johnson N., Sandler H.M., McLaughlin P.W., et al. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys. 38:(2):1997;311-317.
15. Fiveash J.B., Hanks G., Roach M., et al. 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: a multi-institutional review. Int J Radiat Oncol Biol Phys. 47:(2):2000;335-342.
16. Pollack A., Zagars G., Smith J., et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 18:2000;3904-3911.
17. Lawton C.A., Won M., Pilepich M.V., et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys. 21:(4):1991;935-939.
18. Hanlon A.L., Schultheiss T.E., Hunt M.A., et al. Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales. Int J Radiat Oncol Biol Phys. 38:(1):1997;59-63.
19. Zelefsky M.J., Fuks Z., Happersett L., et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol. 55:(3):2000;241-249.
20. Mohan D.S., Kupelian P.A., Willoughby T.R. Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland. Int J Radiat Oncol Biol Phys. 46:(3):2000;575-580.
21. Brenner D.T., Hall E.J. Fractionation and protraction for radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 43:1999;1095-1101.
22. Fuks Z., Leibel S.A., Wallner K.E., et al. The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys. 21:(3):1991;537-547.
23. Holm H.H., Juul N., Pedersen J.F., Hansen H., Stroyer I. Trans-perineal iodine-125 seed implantation in prostate cancer guided by transrectal ultrasonography. J Urol. 130:1983;283-286.
24. Hudson R. Brachytherapy treatments increasing among Medicare population. Health Policy brief. Baltimore, MD: American Urologic Association Inc. 1999; IX: 1.
25. King C.R., Dipetrillo T.A., Wazer D.E. Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models. Int J Radiat Oncol Biol Phys. 46:2000;165-172.
26. King C.R. What is the T(pot) for prostate cancer? Radiobiological implications of the equivalent outcome with (125) I or (103) Pd. Int J Radiat Oncol Biol Phys. 47:2000;1165-1167.
27. Ragde H., Elgamal A.A., Snow P.B., et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer. 83:(5):1998;989-1001.
28. Ragde H., Korb L.J., Elgamal A.A., et al. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer. 89:(1):2000;135-141.
29. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997; 37: 1035-41.
30. Prestidge B.R., Hoak D.C., Grimm P.D., et al. Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. Int J Radiat Oncol Biol Phys. 37:(1):1997;31-39.
31. Stone N.N., Stock R.G. Prostate brachytherapy: treatment strategies. J Urol. 162:(2):1999;421-426.
32. Critz F.A., Williams W.H., Levinson A.K., et al. Simultaneous irradiation for prostate cancer: intermediate results with modern techniques. J Urol. 164:((3 Pt 1)):2000;738-743.
33. Brachman D.G., Thomas T., Hilbe J., Beyer D.C. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys. 48:(1):2000;111-117.
34. Benoit R.M., Naslund M.J., Cohen J.K. Complications after prostate brachytherapy in the Medicare population. Urology. 55:(1):2000;91-96.
35. Duchesne G.M., Peters L.J. What is the a/b ratio for prostate cancer? Rationale for hypofractionated high dose rate brachytherapy. Int J Radiat Oncol Biol Phys. 44:1999;747-748.
36. Stromberg J.S., Martinez A.A., Horwitz E.M., et al. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment. Cancer J Sci Am. 3:(6):1997;346-352.
37. Kestin L.L., Martinez A.A., Stromberg J.S., et al. Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer. J Clin Oncol. 18:(15):2000;2869-2880.
38. Vicini F.A., Kestin L.L., Martinez A.A. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation. Tech Urol. 6:(2):2000;135-145.
39. Mate T.P., Gottesman J.E., Hatton J., et al. High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report. Int J Radiat Oncol Biol Phys. 1:(3):1998;525-533.
40. Dinges S., Deger S., Koswig S., et al. High-dose rate interstitial with external beam irradiation for localized prostate cancer - results of a prospective trial. Radiother Oncol. 48:(2):1998;197-202.
41. Kovacs G., Galalae R., Loch T., et al. Prostate preservation by combined external beam and HDR brachytherapy in nodal negative prostate cancer. Strahlenther Onkol. 175:(Suppl 2):1999;87-88.
42. Borghede G., Hedelin H., Holmang S., et al. Combined treatment with temporary short-term high dose rate iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostatic carcinoma. Radiother Oncol. 44:(3):1997;237-244.
43. Leibel S.A., Hanks G.E., Kramer S. Patterns of care outcome studies: results of the national practice in adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 10:(3):1984;401-409.
44. Nguyen L.N., Pollack A., Zagars G.K. Late effects afterradiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology. 51:(6):1998;991-997.
45. Schultheiss T.E., Lee W.R., Hunt M.A., et al. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 37:(1):1997;3-11.
46. Sandler H.M., McLaughlin P.W., Ten Haken R.K., Addison H., Forman J., Lichter A. Three dimensional conformal radiotherapy for the treatment of prostate cancer: low risk of chronic rectal morbidity observed in a large series of patients. Int J Radiat Oncol Biol Phys. 33:(4):1995;797-801.
47. Wilder R.B., Chou R.H., Ryu J.K., et al. Potency preservation after three-dimensional conformal radiotherapy for prostate cancer: preliminary results [In Process Citation]. Am J Clin Oncol. 23:(4):2000;330-333.
48. Boersma L.J., van den B.M., Bruce A.M., et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys. 41:(1):1998;83-92.
49. Blasko J.C., Ragde H., Grimm P.D. Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. Scand J Urol Nephrol Suppl. 137:1991;113-118.
50. Gelblum D.Y., Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 48:(1):2000;119-124.